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The acronym “ALPPS” was coined by de Sanibanes and Clavien in 2012 to describe surgery 
which involved “Associating Liver Partition and Portal vein ligation for Staged hepatectomy” 
following on from the initial reports over the previous two years from both Germany and 
Argentina.
1,2,3
  The development of ALPPS appears to have been at least in part by 
serendipity: initially described in a single patient with perihilar cholangiocarcinoma and then 
tested in a series of patients with extensive colorectal liver metastases.  Early reports 
suggested there was a very high risk or peri-operative mortality but at the same time it 
appeared to offer hope for patients with a high burden of disease and as a result there were 
both strong proponents and opponents for this innovative procedure at an early stage and 
much argument remains today.  Whilst surgeons have often been criticised for poor 
scientific approaches to clinical research, we are driven by a passion to improve patient care 
in difficult situations.  With ALPPS we have seen an excellent example of diffusion of 
innovation theory and we remain in limbo with an ongoing battle between relatively few 
early adopters and many sceptics and laggards.
 4
  Yet ALPPS is here to stay as a useful 
surgical advance and with the successive development of modifications, again through 
innovation, it is now clear that the early fears of excessive mortality should be laid to rest.  
In considering the case for ALPPS it is important to review these developments and 
understand properly how each has made a contribution as this is an argument that needs to 
be settled.   This is important as there is no doubt that opinion leaders can influence 
adoption of new techniques. 
 
There is no doubt that the majority of the early reports relating to ALPPS were associated 
with a high risk of per-operative mortality.  In 2012, Schnitzbauer et al described a 
collaborative German experience of 25 patients with 3 early deaths (12% peri-operative 
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mortality) and a complication rate of 68%, but survival at 6 months was 86% for this group 
of apparently otherwise inoperable cases.
2
  It is important to note, however, that the three 
patients who died accounted for 40% of all of the complications, all three had undergone 
neoadjuvant chemotherapy for colorectal liver metastases, and the deaths were related to 
biliary complications and sepsis.  The major impact of this report related not only what 
seemed at the time to be an unusual level of risk but also more positively to the rapid future 
liver remnant (FLR) hypertrophy that occurred over a median of only 9 days, although the 
second stage was carried out over a large range of 5 to 28 days. de Sanibanes and Clavien 
subsequently suggested that a 7 day interval between the two stages is enough but this 
remains an area for debate.
1
   
 
There are three ways that the results for ALPPS can be improved: patient selection, timing 
of the second stage and modification of the surgical technique.  Work has been done on all 
of these aspects and not least in patient selection. 
 
If we are to move forward successfully with ALPPS then patient selection will be paramount 
both in terms of avoiding peri-operative mortality but also for improved long term 
outcomes.   A so called “futility risk score” has been proposed for reducing peri-operative 
mortality and this suggests caution for older patients and those with biliary tract cancer but 
more work needs to be done.
5
  Data from the International ALPPS Registry suggests better 
outcomes with colorectal metastases cases but this is also where we have most experience 
with multi stage liver surgery of any type.
6
  There is no doubt that in the initial experiences 
the rates of early tumour recurrence were too great but this is improving with time with 
better patient selection.  It is currently not clear if there is a true advantage to ALPSS versus 
a more classical two stage approach but emerging data suggest that there are higher 
completion rates for the second stage surgery with ALPPS, although at a cost of a higher 
complication rate.  We should not forget, however, that when two stage liver surgery was 
introduced there were reports of high peri-operative mortality and uncertain long term 
outcomes yet today this technique is widely accepted so with more careful exploration 
ALPPS too should earn its rightful place in hepatic surgery.   
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Timing for the second stage of ALPPS is a subject of ongoing discussion.  The initial reports 
included manoeuvres including complete right liver mobilisation and enclosing the liver to 
be subsequently resected in a plastic bag to prevent adhesions and it was also thought that 
biliary drainage may be helpful.  Today, most of us would agree that it is safer to carry out a 
less invasive first stage, not to mobilise the right liver, and to use haemostatic materials 
between the cut parenchymal surfaces as an easier and safer procedure.  This allows more 
options when considering timing of the second stage, which is the operation with the 
greatest impact physiologically in my experience.  When considering the correct timing for 
the second stage, ALPPS appears to engender a more rapid an improved future liver 
remnant volume than portal vein embolisation alone.  Indeed, in Schnitzbauer’s original 
description the median hypertrophy was 74% after an interval of only nine days, and this 
has been confirmed by a recent meta-analysis.
7
  But, we have to question if hypertrophy as 
seen on a CT scan will translate to adequate post resection liver function.  This is an 
important point as there is much remaining argument about whether volumetry or 
functional analysis of the FLR is more important: does hypertrophy actually mean 
predictable improved FLR function at an early stage or should we wait longer?  Tanaka has 
suggested that we should be cautious as functional changes in the FLR lag behind changes in 
volume.
8
  My own opinion is that we should indeed wait longer and I suggest that surgeons 
should consider that a “delayed ALPPS” approach is safer: in my experience a wait time of 
14 days does not increase operative difficulty and it carries with it the benefit of easy 
scheduling, whilst allowing the patient some time at home between stages.  We also know 
that successful outcomes are possible with “rescue ALPPS” for patients that have previously 
failed to achieve adequate FLR hypertrophy with portal vein embolisation. 
 
With any new surgical procedure there will be inevitable alterations in technique suggested 
to improve outcomes.  There have been recent reports of  zero peri-operative mortality  in 
series of carefully selected patients with success was partly attributed to careful 
preservation of the middle hepatic vein during the first stage.  This more partial hepatic 
transaction at stage one was highlighted by Clavien’s group in 2015 as partial ALPPS (or p-
ALPPS) and described as a 50-80% transaction associated with a reduction in mortality from 
22% down to zero so this was a significant observation.
9
 Importantly, FLR hypertrophy does 
not appear to be compromised by this technique.  Others have described this approach as a 
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“mini-ALPPS” and the aim has been to limit morbidity between the two stages.  Most 
recently, the minimal invasive approach of laparoscopic ALPPS has also emerged as a way of 
reducing the morbidity of both stages.  These are significant advances that must not be 
ignored.  At the more radical end, “monosegment ALPPS” and “hybrid ALPPS” also deserve 
consideration.  Schadde et al reported 12 cases of monsegment ALPPS from the 
international ALPPS registry, leaving a single hepatic segment FLR, with no operative 
mortality in 2015.
10
  It is clear that careful patient selection and meticulous surgical 
technique was required.   A further consideration is a “hybrid ALPPS” approach for cases 
where the portal bifurcation is involved with tumour and right portal vein ligation cannot be 
achieved without tumour compromise: here there are options of portal vein embolisation or 
portal vein division and re-anastomosis to occlude the portal supply to the liver to be 
removed at the second stage.  The reality is that all of these techniques are useful and a 
surgeon undertaking ALPPs must be aware of new developments to maximise patient 
safety.  
 
Finally, we must consider the place of ALPPS.  There is no doubt that these complex 
procedures must only be undertaken by experienced surgeons in a high-volume centres, 
and patient selection should be by means of a multidisciplinary team effort.  The 
management careful of these patients during the postoperative course of both surgical 
procedures is crucial to achieve success.   With increasing experience, ALPPS will define its 
own place in the surgical armamentarium.  Whist it is true that advances in chemotherapy 
mean that more major resections are undertaken less often these days, as liver surgeons we 
are faced with unexpected challenges and it is only through innovation that we can rise to 
the task in hand.  ALPPS in its many forms is here to stay but I suspect there will be an 
increasing recognition that more careful patient selection along with a more minimal first 
stage (laparoscopic, partial and mini ALPPS) and a less urgent approach to the second stage 
(delayed ALPPS) will be rewarded by improved success. 
 
References: 
1.  de Santibanes E, Clavien P-A. Playing Play-Doh to Prevent Postoperative Liver Failure  
- The “ALPPS” approach. Ann Surg 2012; 255: 415-417 
M
A
N
U
S
C
R
IP
T
 
A
C
C
E
P
T
E
D
ACCEPTED MANUSCRIPT
2. Schnitzbauer AA, Lang SA, Goessmann H, Nadalin S, et al. Right portal vein ligation 
combined with in situ splitting induces rapid left lateral liver lobe hypertrophy 
enabling 2-staged extended right hepatic resection in small-for-size settings. Ann 
Surg. 2012 Mar;255(3):405-414. 
3. de Sanibanes E, Alvarez FA, Ardiles V.  How to avoid postoperative liver failure : a 
novel method.  World J Surg 2012; 36: 125-128, 
4. Rogers, E. M. & Shoemaker, F. F. (1971). Communication of Innovation. New York: 
The Free Press.  
5. Linecker M, Stavrou GA, Oldhafer KJ, wt al. The ALPPS Risk Score: Avoiding Futile Use 
of ALPPS. Ann Surg. 2016 Nov;264(5):763-771.  
6. Schadde E, Ardiles V, Robles-Campos R. Et al on behalf of the ALPPS Registry Group.  
Early survival and safety of ALPPS: First report of the international ALPPS registry.  
Ann Surg 2014; 260: 829-838. 
7. .Eshmuminov D, Raptis DA, Linecker M, et al.  Meta-analysis of associating liver 
partition with portal vein ligation and portal vein occlusion for two-stage 
hepatectomy. Br J Surg. 2016 Sep 16. doi: 10.1002/bjs.10290. [Epub ahead of print] 
Review. PubMed PMID: 27633328. 
8. Tanaka K, Matsuo K, Murakami T et al.  Associating  liver partition and portal vein 
ligation for staged hepatectomy (ALPPS): Short-term outcome, functional changes in 
the future liver remnant, and tumor growth activity.  EJSO 2015; 41:506-512 
9. Petrowsky H, Gyori G, de Oliveira M et al.  Is partial-LPPS safer than ALPPS? A single-
center experience. Ann Surg 2015; 4: e90-92. 
10. Schadde E, Malago M, Hernandez-Alejandro R, et al. Monosegment ALPPS  
hepatectomy : extending resectability by rapid hypertrophy.  Surgery 2015; 157: 676-
689. 
